Some lawmakers and advocates are increasingly uncertain whether critical HIV and AIDS services will survive the federal government’s funding fight. The GOP’s House-passed budget bill seeks to cut ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

The timing of the renewed support is pivotal. South Africa is preparing to roll out Lenacapavir, a groundbreaking long-acting antiretroviral treatment, as early as March or April 2026.

When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in January this year, we immediately set about finding solutions. Among the most pressing was to ...

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

The South African Health Products Regulatory Authority (SAHPRA) has registered the drug Lenacapavir, which the World Health ...

It is believed the lenacapavir shot could end HIV/Aids in the country within 14 to 18 years if enough people were to take it.

South Africa has become the first African country — and our medicines regulator the third worldwide — to register the ...

The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...

SAHPRA has registered Lenacapavir, a new six-monthly PrEP injection to prevent HIV-1 in adults and adolescents over 35 kg.